Posted on 3 December 2025 by Northern RNA
CALGARY, Canada and AMES, United States – 3 December 2025 – Northern RNA, a Canadian-based contract development and manufacturing organization (CDMO) specializing in GMP production of RNA-based therapeutics and Genvax Technologies, a startup animal health company specializing in custom prescription livestock vaccines have today announced a strategic collaboration agreement.
This agreement marks a significant milestone in Genvax’s mission to transform animal health. The company’s first product an RNA-based swine influenza vaccine is currently undergoing regulatory review and is expected to launch in 2027. Genvax Technologies has developed proprietary next-generation RNA and nanoparticle vaccines in which they can create vaccines at 33% of the development time of their competitors and be fully customized to each herd’s disease outbreak.
Under this collaboration, Northern RNA will serve as Genvax’s contract manufacturer, providing scalable production of the proprietary lipid used to encapsulate their RNA-based swine influenza vaccine. Northern RNA’s expertise and state-of-the-art manufacturing capabilities will play a vital role in supporting Genvax’s commercialization efforts.
“We couldn’t ask for a better partner than Northern RNA as we bring our first saRNA-based animal vaccine to market,” said Joel Harris, CEO and Co-Founder of Genvax Technologies. “Their team understands the urgency and impact of our mission. Together, we’re creating a faster, smarter way to protect livestock and the global food supply from emerging diseases.
“Northern RNA is thrilled and committed to support Genvax in delivering innovative RNA vaccines to the animal health market,” said Dr. Jared Davis, President and CTO of Northern RNA. “This partnership reflects our shared commitment to leveraging RNA technologies for impactful, real-world applications. With our GMP-grade facilities and expertise, we are proud to help accelerate the availability of Genvax’s cutting-edge solutions.”
This collaboration underscores Northern RNA’s ongoing commitment to empowering biotech innovators by offering end-to-end manufacturing solutions from process development through to commercial-scale production. The company’s flexible approach enables clients like Genvax to bring high-quality RNA products to market faster, more efficiently, and at scale.
Contact Information
About Northern RNA
Founded in 2020 to address unmet global demand for the manufacturing of vaccines and vaccine components, Northern RNA is a leading Contract Development and Manufacturing Organization (CDMO) specializing in the production of nucleic acid products used in applications including mRNA vaccines, DNA vaccines, mRNA therapies, gene editing, and gene therapies. Our goal is to provide secure, clinical-to-commercial scale, GMP-grade manufacturing for our customers across the globe. For more information about our end-to-end CDMO capabilities, please follow us on LinkedIn or visit us at www.northernrna.com.
About Genvax
Genvax is a startup animal vaccine company located in Ames, Iowa, with a dynamic team of experienced scientists and entrepreneurs dedicated to developing next-generation RNA vaccines.
LinkedIn: https://www.linkedin.com/company/
Genvax Website: http://www.genvax.com/
#CDMO #RNA #mRNA #LNP #Lipids #oligo #Biomanufacturing #DrugDevelopment #Animalhealth #Zoonoticdiseases #ManufacturingABetterFuture #saRNA #AgTech